article thumbnail

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

The Pharma Data

This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development. About Twist Bioscience Corporation.

article thumbnail

Evotec Achieves Key Milestones in Its Collaboration with Bristol Myers Squibb On Targeted Protein Degradation

The Pharma Data

Additionally, Evotec is entitled to tiered, potentially double-digit royalties of the net sales of programmes developed under the partnership. ” ABOUT PANOMICS/PANHUNTER PanOmics involves the innovative use of genomics, transcriptomics, proteomics, and phenotypic data in an integrated fashion.

Protein 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug discovery’s latest top-level appointments

Drug Discovery World

Bironneau brings over two decades of commercial leadership experience, including as Vice President, Global Sales & Business Development at Axplora and Novasep. She previously worked at Vertex Pharmaceuticals as VP Global Marketing, and at Zealand Pharma as VP, US Sales and Marketing.

Drugs 52
article thumbnail

Top 10 Fastest Growing Biotech Companies in 2023

XTalks

In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. Furthermore, Fulgent has raised its full-year 2023 core revenue guidance to $260 million while simultaneously narrowing its financial losses.

Genetics 111
article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Jae Seong Lee, PhD, Associate Professor, Applied Chemistry & Biological Engineering, Ajou University, on: “Genome-wide virus-free CRISPR screening platform for identifying novel engineering targets in mammalian cells”. The presentations which follow include: Peter Tessier, PhD, Albert M.